FL118 targeting the BIRC5 promotor has been linked to transcriptional inhibition, and anti-tumour activity, in multiple cancer types, including cervical and pancreatic cancer and leukaemia [68,69,70]. This evidence concerns the gene BIRC5 and leukemia.